[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Glaukos Corp (GKOS)

Glaukos Corp (GKOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 125.00 (+2.72%)
Glaukos: Q1 Earnings Snapshot

Glaukos: Q1 Earnings Snapshot

GKOS : 125.00 (+2.72%)
Glaukos Announces First Quarter 2026 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 125.00 (+2.72%)
Glaukos Reports Tomorrow With Epioxa Launch Metrics Still Unknown

Barchart Research What to Expect from GKOS Earnings GKOS Generated April 28, 2026 Current Price $119.63 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 9.55% Glaukos Reports Tomorrow With...

GKOS : 125.00 (+2.72%)
Glaukos Announces the Release of its 2025 Sustainability Report

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 125.00 (+2.72%)
Glaukos Receives Permanent J-code for Epioxa™

New J-code for Epioxa ™ , J2789, set to become effective July 1, 2026

GKOS : 125.00 (+2.72%)
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

Conference Call and Webcast Scheduled for 1:30 p.m. PT

GKOS : 125.00 (+2.72%)
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced...

GKOS : 125.00 (+2.72%)
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare Disease

GKOS : 125.00 (+2.72%)
Glaukos: Q4 Earnings Snapshot

Glaukos: Q4 Earnings Snapshot

GKOS : 125.00 (+2.72%)

Barchart Exclusives

Why Coca-Cola and Walmart Top This List of Steady, Low-Volatility Dividend Aristocrats
Dividend Aristocrats can offer income, stability, and consistency. Here are four lower-volatility names analysts still like. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.